Cubist Pharmaceuticals Inc : Cubist Pharmaceuticals Appoints Alison Lawton to Board of Directors

02/16/2012| 08:05am US/Eastern

Recommend:

0

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the appointment of Alison Lawton to its Board of Directors. Ms. Lawton is currently Senior Vice President, General Manager Biosurgery, at Genzyme Corporation (now part of Sanofi). With the addition of Ms. Lawton, the Cubist Board of Directors consists of 10 members, nine of whom are independent.

"Alison's tremendous breadth and depth of experience in international regulatory affairs and operations adds an important and complementary skill set to the Cubist Board," said Kenneth Bate, non-executive Chairman of the Board of Directors of Cubist. "As we prepare for future product launches on a global scale, Alison's counsel will be invaluable to the Company."

Ms. Lawton joined Genzyme in 1991 as an international regulatory affairs specialist. As head of Genzyme Biosurgery, Ms. Lawton is responsible for Genzyme's global orthopedics, biosurgical specialty (BSS) and cell therapy and regenerative medicine (CT&RM) businesses. The orthopedic business includes the Synvisc and Jonexa franchises; the BSS business consists of Seprafilm; and the CT&RM products include the autologous cell therapies Carticel, MACI and Epicel. Prior to this role, Ms. Lawton oversaw Global Market Access at Genzyme, which included Regulatory Affairs, Global Health Outcomes and Strategic Pricing, Global Public Policy and Global Product Safety & Risk Management. Before joining Genzyme, Ms. Lawton worked for seven years at Parke-Davis in the United Kingdom. She has a bachelor's degree in Pharmacology from the University of London.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist's web site at www.cubist.com.

INVESTORS:
Cubist Pharmaceuticals, Inc.
Eileen C. McIntyre, 781-860-8533
Senior Director, Investor Relations
eileen.mcintyre@cubist.com
or
MEDIA:
Cubist Pharmaceuticals, Inc.
Francis McLoughlin, 781-860-8777
Director, Corporate Communications
Francis.mcloughlin@cubist.com

0